Literature DB >> 25122423

Inherited variation in the ATP-binding cassette transporter ABCB1 and survival after chemotherapy for stage III-IV lung cancer.

Joel L Weissfeld1, Brenda Diergaarde, Tomoko Nukui, Shama Buch, Arjun Pennathur, Mark A Socinski, Jill M Siegfried, Marjorie Romkes.   

Abstract

BACKGROUND: The ATP-binding cassette transporter gene ABCB1 and the glutathione S-transferase gene GSTP1 code for a multidrug resistance protein and for a detoxifying phase II metabolic enzyme, respectively, with substrate specificities that include chemotherapy drugs often used to treat lung cancer.
METHODS: We genotyped 11 ABCB1 and eight GSTP1 single nucleotide polymorphisms (SNPs) in 698 white lung cancer patients (all current or former cigarette smokers) and used log-rank test statistics and proportional hazards regression to evaluate associations between SNP genotype and survival.
RESULTS: Using data from all 698 cases, one SNP in ABCB1 (rs2235013) was statistically significantly associated with overall survival (p = 0.038, log-rank test). Chemotherapy and stage jointly (p = 0.025) significantly modified the association between rs2235013 and survival, with statistically significant (p = 0.013, log-rank test) association observed in the subgroup of stage III to IV lung cancer patients who received chemotherapy as part of their first course of treatment (n = 160; 93.1% nonsmall cell). Patients who inherited the minor T allele at ABCB1 rs2235013 experienced better overall survival and recurrence-free survival (hazard ratio, per minor T allele, [95% confidence interval]: 0.66 [0.49-0.90] and 0.55 [0.31-0.95], respectively; adjusted for year of diagnosis, sex, age at diagnosis, cigarette pack years, and stage). In addition, in the advanced stage chemotherapy-treated subgroup, four ABCB1 SNPs (rs6949448, rs2235046, rs1128503, and rs10276036) in mutual high linkage disequilibrium with rs2235013 and an independent ABCB1 SNP (rs1045642) showed statistically significant association (p < 0.05) with survival.
CONCLUSIONS: Inherited variation in ABCB1 may affect survival specifically in advanced stage lung cancer patients who receive chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25122423      PMCID: PMC4134100          DOI: 10.1097/JTO.0000000000000262

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  28 in total

Review 1.  Taxanes for advanced non-small cell lung cancer.

Authors:  Sakkaraiappan Ramalingam; Chandra P Belani
Journal:  Expert Opin Pharmacother       Date:  2002-12       Impact factor: 3.889

Review 2.  ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research.

Authors:  G D Leschziner; T Andrew; M Pirmohamed; M R Johnson
Journal:  Pharmacogenomics J       Date:  2006-09-12       Impact factor: 3.550

Review 3.  Role of taxanes in the combined modality treatment of patients with locally advanced non-small cell lung cancer.

Authors:  H Choy; H Pyo; J S Kim; R MacRae
Journal:  Expert Opin Pharmacother       Date:  2001-06       Impact factor: 3.889

4.  MDR1 single nucleotide polymorphism G2677T/A and haplotype are correlated with response to docetaxel-cisplatin chemotherapy in patients with non-small-cell lung cancer.

Authors:  Ji-Hong Pan; Jin-Xiang Han; Jian-Mei Wu; Hai-Nan Huang; Qing-Zhong Yu; Li-Jun Sheng
Journal:  Respiration       Date:  2008-09-24       Impact factor: 3.580

Review 5.  A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function.

Authors:  King Leung Fung; Michael M Gottesman
Journal:  Biochim Biophys Acta       Date:  2009-03-11

6.  Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer.

Authors:  D Isla; C Sarries; R Rosell; G Alonso; M Domine; M Taron; G Lopez-Vivanco; C Camps; M Botia; L Nuñez; M Sanchez-Ronco; J J Sanchez; M Lopez-Brea; I Barneto; A Paredes; B Medina; A Artal; P Lianes
Journal:  Ann Oncol       Date:  2004-08       Impact factor: 32.976

7.  MDR1 single nucleotide polymorphisms predict response to vinorelbine-based chemotherapy in patients with non-small cell lung cancer.

Authors:  Ji-hong Pan; Jin-xiang Han; Jian-mei Wu; Li-jun Sheng; Hai-nan Huang; Qing-zhong Yu
Journal:  Respiration       Date:  2007-09-12       Impact factor: 3.580

8.  Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group.

Authors: 
Journal:  BMJ       Date:  1995-10-07

9.  Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer.

Authors:  Ji-Youn Han; Hyeong-Seok Lim; Yeon-Kyeong Yoo; Eun Soon Shin; Yong Hoon Park; Sung Young Lee; Jong-Eun Lee; Dea Ho Lee; Heung Tae Kim; Jin Soo Lee
Journal:  Cancer       Date:  2007-07-01       Impact factor: 6.860

10.  Platinum pathway.

Authors:  Sharon Marsh; Howard McLeod; Eileen Dolan; Sunita J Shukla; Cara A Rabik; Li Gong; Tina Hernandez-Boussard; Xing Jian Lou; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2009-07       Impact factor: 2.089

View more
  1 in total

1.  The impact of ABCB1 gene polymorphism and its expression on non-small-cell lung cancer development, progression and therapy - preliminary report.

Authors:  Izabela Zawadzka; Agnieszka Jeleń; Jacek Pietrzak; Marta Żebrowska-Nawrocka; Katarzyna Michalska; Dagmara Szmajda-Krygier; Marek Mirowski; Mariusz Łochowski; Józef Kozak; Ewa Balcerczak
Journal:  Sci Rep       Date:  2020-04-10       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.